术前大麻使用对胃轻瘫手术结局的影响
基于TriNetX电子病历数据库的回顾性队列研究,纳入1572例接受幽门引流手术或胃电刺激器植入的胃轻瘫成人患者,其中108例(6.9%)术前有大麻使用记录。结果显示术前大麻使用与更高症状负担、90天内再干预和住院增加、门诊随访减少及5年住院率升高相关,而胃切除率和晚期再干预率两组相似。
要点
- 术前大麻使用与胃轻瘫术后90天内再干预率升高相关(9.3% vs 1.2%)。
- 大麻使用组5年住院率更高(59.3% vs 41.0%),门诊随访参与更少。
- 此类患者症状负担更重,建议加强术后随访以减少再入院。
核心结论
- 术前大麻使用与胃轻瘫手术后更高的症状负担、早期再干预增加、门诊参与减少及长期医疗利用增加相关。
- 两组胃切除率(0.0% vs 0.7%)与晚期再干预率(12.0% vs 11.3%)相似。
研究设计与样本
- 回顾性队列研究,使用TriNetX联邦电子病历数据库。
- 纳入接受幽门引流手术或胃电刺激器植入的胃轻瘫成人患者,按术前大麻使用(ICD-10 F12)分层,共1572例,其中108例(6.9%)有术前大麻使用记录。
- 结局评估覆盖术后前90天及最长5年,统计方法包括风险分析、Kaplan-Meier生存分析和事件次数。
主要发现
- 大麻使用组更年轻(39.8 vs 44.6岁,p=0.002),糖尿病(56.5% vs 45.1%,p=0.033)、GERD(77.7% vs 65.1%,p=0.014)、恶心呕吐(85.2% vs 59.4%,p<0.001)及腹痛(73.1% vs 50.2%,p<0.001)比例更高。
- 90天内大麻使用组再干预率更高(9.3% vs 1.2%,p<0.001),住院率更高(32.4% vs 23.7%,p=0.042),门诊就诊更少(37.0% vs 54.5%,p<0.001)。
- 5年内大麻使用组住院率更高(59.3% vs 41.0%,p<0.0001),首次住院时间更短(log-rank p<0.001)。
- 5年内大麻使用组随访率更低(54.6% vs 76.2%,p<0.001),总门诊就诊次数更少(8.1 vs 12.3,p=0.045),首次门诊就诊时间更长(log-rank p<0.001)。
临床怎么用
- 对术前有大麻使用的胃轻瘫手术患者,应认识到其症状负担更重、早期再干预和住院风险更高。
- 可考虑对这类患者加强术后随访和门诊管理,以减少再入院和改善医疗利用。
局限性
- 为回顾性队列研究,大麻使用依据ICD-10编码识别,可能存在漏识别或错分。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cannabis use has been associated with delayed gastric emptying and may worsen symptoms in patients with gastroparesis. However, its impact on postoperative outcomes after surgical treatment remains unclear. This study aimed to evaluate postoperative outcomes among patients with and without preoperative cannabis use undergoing surgical intervention for gastroparesis. METHODS: A retrospective cohort study was conducted using the TriNetX federated electronic medical record database. Adults with gastroparesis who underwent pyloric drainage surgery or gastric stimulator placement were stratified by cannabis use (ICD-10 F12) prior to surgery. Outcomes were assessed over the first 90 days and up to 5 years postoperatively. Statistical comparisons included risk analysis, Kaplan-Meier survival, and number of instances. RESULTS: The study cohort consisted of 1,572 patients, including 108 (6.9%) with documented preoperative cannabis use. Patients with cannabis use were younger (39.8 vs 44.6 years, p = 0.002) and had higher rates of diabetes (56.5% vs 45.1%, p = 0.033), GERD (77.7% vs 65.1%, p = 0.014), nausea/vomiting (85.2% vs 59.4%, p < 0.001), and abdominal pain (73.1% vs 50.2%, p < 0.001). Within 90 days of surgery, cannabis users experienced higher rates of reintervention (9.3% vs 1.2%, p < 0.001) and inpatient admissions (32.4% vs 23.7%, p = 0.042), but fewer clinic visits (37.0% vs 54.5%, p < 0.001). By 5 years, cannabis users demonstrated persistently greater inpatient utilization with higher hospital admission rates (59.3% vs 41.0%, p < 0.0001) and shorter time to first admission (log-rank p < 0.001). Outpatient engagement was significantly lower, with fewer patients attending follow-up (54.6% vs 76.2%, p < 0.001), fewer total clinic encounters (8.1 vs 12.3, p = 0.045), and longer time to first clinic visit (log-rank p < 0.001). Rates of gastrectomy (0.0% vs 0.7%, p = 0.541) and late reintervention (12.0% vs 11.3%, p = 0.808) were similar between groups. DISCUSSION: Preoperative cannabis use is associated with a greater symptom burden, increased early reintervention, reduced outpatient engagement, and greater long-term healthcare utilization after surgical intervention for gastroparesis. These patients may represent a more symptomatic population and may benefit from closer follow-up to reduce readmissions.
引用
- Eriksson SE, Chaudhry N, Gardner ME, et al. Impact of preoperative cannabis use on outcomes following surgical intervention for gastroparesis. Surg Endosc. 2026. PMID: 41559335. doi:10.1007/s00464-025-12558-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。